Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands
American Journal of Cardiovascular Drugs · 2025
DOI: 10.1007/s40256-025-00749-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cardiovascular Drugs, 2025. Verfasst von Bart P H Slob und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health-Ecore B.V., Zeist, The Netherlands. Bartslob@health-ecore.com. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
OBJECTIVE: Clinical trials have demonstrated the efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin in patients suffering from heart failure (HF), regardless of whether their left-ventricle ejection fraction (LVEF) is reduced (HFrEF), mildly reduced (HFmrEF), or preserved (HFpEF). This study aims to assess the cost-effectiveness of empagliflozin when added to standard of care (SoC), consisting of lifestyle changes, medications, and surgery or devices, compared to SoC alone in patients with chronic HF irrespective of LVEF in the Netherlands. METHODS: A Markov model was developed to simulate patient outcomes over a lifetime horizon, incorporating data from the EMPEROR-Reduced and EMPEROR-Preserved trials. Key outcomes included incremental cost-effectiveness ratios (ICERs) expressed in costs per quality-adjusted life-year (QALY) gained, life expectancy, and hospitalization rates. Probabilistic and one-way sensitivity analyses were conducted to assess the robustness of the results. RESULTS: The analysis revealed that treatment with empagliflozin plus SoC resulted in higher life expectancy (6.58 vs. 6.47 years for HFrEF; 7.78 vs. 7.69 years for HFmrEF/HFpEF) and a lower incidence of HF hospitalizations compared to SoC alone. The ICERs were €8515/QALY for HFrEF and €9807/QALY for HFmrEF/HFpEF, both below the willingness-to-pay threshold of €50,000/QALY, indicating cost-effectiveness. Sensitivity analyses confirmed the robustness of the results, indicating there is a high probability (97% for HFrEF and 98% for HFmrEF/HFpEF) that empagliflozin plus SoC is cost-effective. CONCLUSION: Empagliflozin, when added to SoC, is a cost-effective treatment option for patients irrespective of LVEF in the Netherlands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health-Ecore B.V., Zeist, The Netherlands. Bartslob@health-ecore.com.
- Department of Health Sciences, Global Health Unit, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands. Bartslob@health-ecore.com.
- Health-Ecore B.V., Zeist, The Netherlands.
- Department of Health Sciences, Global Health Unit, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
- Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, 9747 AE, Groningen, The Netherlands.
- Boehringer Ingelheim bv., Amsterdam, The Netherlands.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Slob, B. P. H., Postma, M. J., Weersma, M., Rocca, H. B., de Jong, L. A., & Boersma, C. (2025). Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-025-00749-6
Vancouver
Slob BPH, Postma MJ, Weersma M, Rocca HB, de Jong LA, Boersma C. Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands. American Journal of Cardiovascular Drugs. 2025. doi:10.1007/s40256-025-00749-6
BibTeX
@article{Slob2025,
author = {Slob, Bart P H and Postma, Maarten J and Weersma, Maaike and Rocca, Hans-Peter Brunner-La and de Jong, Lisa A and Boersma, Cornelis},
title = {Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands},
journal = {American Journal of Cardiovascular Drugs},
year = {2025},
doi = {10.1007/s40256-025-00749-6}
}
EUVIMED